• Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?

  • Aug 20 2024
  • Length: 25 mins
  • Podcast

Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?

Listen for free

View show details

  • Summary

  • Drs Kathy D. Miller and Sunil S. Badve discuss the importance of identifying HER2-low patients, those with ultra-low staining, and the benefit of targeted ADCs.

    Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001160. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

    Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update https://pubmed.ncbi.nlm.nih.gov/37284804/

    T-DXd Improves Progression-Free Survival in Patients With Breast Cancer Previously Treated With Endocrine Therapy https://ascopost.com/news/june-2024/t-dxd-improves-progression-free-survival-in-patients-with-breast-cancer-previously-treated-with-endocrine-therapy/

    Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients With Residual HER2-Positive Invasive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34636255/
    Show more Show less
Show more Show less

What listeners say about Breast Cancer and HER2-Low: A Distinct Biology or an Artifact of Testing?

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available